Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Moffitt, Vermillion Collaborate to Model Improvements in Ovarian Cancer Care

Published: Monday, May 12, 2014
Last Updated: Monday, May 12, 2014
Bookmark and Share
The purpose of the study is to produce clinical and economic data to support a new value-based practice model.

The study will be led by Johnathan M. Lancaster, M.D., Ph.D., a gynecologic oncologist, expert in personalized medicine and president of the Moffitt Medical Group, and funded through an unrestricted grant fromAustin-based Vermillion, Inc. It will feature two phases, the first phase will be retrospective, and will benchmark the care standards and variances provided to patients with ovarian, fallopian tube and/or primary peritoneal cancer. The second phase will model improvements in care quality and cost that may be afforded by creating a standardized triage algorithm employing different FDA-cleared or prototype multi-marker blood tests, along with established clinical diagnostic or prognostic factors such as pelvic exams and ultrasound imaging.

"It is imperative that we rapidly develop high-quality, cost-effective strategies for the diagnosis and treatment of ovarian cancer," said Dr. Lancaster. "Multiple studies have shown that patients with ovarian cancer who are treated from the beginning by a board-certified gynecologic oncologist have a better chance of beating the disease. Yet in the U.S., fewer than half of the patients with the disease receive care from a gynecologic oncologist. This likely contributes to the high death rate from the disease, and is simply unfair to patients.  We have a duty to develop clinical management strategies that will change this pattern – to improve survival rates, quality of life, and the cost-effectiveness of care in our communities."

Nearly 22,000 women are diagnosed with ovarian cancer in the U.S. annually, and more than 14,000 die each year, making it the deadliest of all gynecologic cancers. Treatment advances during the last three decades have modestly improved the average length of survival following a diagnosis of ovarian cancer. Women diagnosed with ovarian cancer in 1975 had a five-year survival rate of 33.6 percent. Today, the rate is still only 44 percent.

"Today, on World Ovarian Cancer Day, we honor the thousands of women who have lost their lives to ovarian cancer, as well as the women, their families and care teams who are fighting this disease," said James LaFrance, chairman, president and chief executive officer of Vermillion. "Reducing the burden of ovarian cancer is central to our mission and to the health of women in the U.S. With the expertise of Dr. Lancaster and the Moffitt team, we believe this effort will facilitate an important dialogue and establish a path to improving ovarian cancer care and outcomes."

The study will measure the baseline triage effectiveness, treatment standards, early outcomes and cost of care for patients diagnosed with an adnexal malignancy. From this baseline, potential improvement in care and cost effectiveness will be calculated for different triage protocols, including molecular or proteomic biomarkers, such as the OVA1® blood test. OVA1 is an FDA-cleared, highly sensitive blood test that offers a way to predict whether a suspicious pelvic mass is malignant or benign, helping triage a woman to a gynecologic oncologist more quickly. OVA1 measures the levels of five tumor-secreted proteins (Beta-2 microglobulin, CA 125II, apolipoprotein A1, prealbumin and transferrin), while measuring the host response to ovarian cancer. Studies have shown that OVA1 improves the pre-surgical detection of ovarian cancer, regardless of stage or subtype, in patients with planned surgery for a suspicious mass.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protein Complex Linked to Cancer Growth May Also Help Fight Tumors
Researchers have discovered a gene expression signature that may lead to new immune therapies for lung cancer patients.
Thursday, July 25, 2013
Moffitt Cancer Center Researchers Identify Genetic Variants for Prostate Cancers
Researchers have developed a method for identifying aggressive prostate cancers that require immediate therapy.
Monday, June 24, 2013
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos